Phoebe Putney Memorial Hospital

Summary

Phoebe Putney Memorial Hospital is a medical facility located in Albany, Georgia. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Phoebe Putney Memorial Hospital is involved with conducting 72 clinical trials across 115 conditions. There are 2 research doctors associated with this hospital, such as Sharad Ghamande and Vamsi Kota, MD.

Top PIs

Clinical Trials running at Phoebe Putney Memorial Hospital

Breast Cancer

Acute Myeloid Leukemia

Breast cancer

Cancer

Acute Myelogenous Leukemia

Myelodysplastic Syndrome

Pancreatic Cancer

Myeloproliferative Disorder

Acute Myeloid Leukemia or Myelodysplasia-Related Acute Myeloid Leukemia

Colon Cancer

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria